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1. INTRODUCTION {#cam42139-sec-0005}
===============

Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 3%‐4% of all new cancer cases in the Unites States.[1](#cam42139-bib-0001){ref-type="ref"} Around 60% of these patients present with locally advanced disease. Meta‐Analysis of Chemotherapy in Head and Neck Cancer (MACH‐NC) has shown improvement in absolute survival by 4.5% with systemic therapy when utilized concurrently with radiation. Therefore these patients are primarily treated with concurrent chemotherapy and radiotherapy (CRT) to preserve organ function. However, an optimal systemic therapy is not well defined. Regimens that were associated with benefit include platinum‐based monotherapy or polychemotherapy regimens containing platinum or fluorouracil (5‐FU) or both.[2](#cam42139-bib-0002){ref-type="ref"} Due to lack of prospective data, high‐dose cisplatin 100 mg/m^2^ (Cis) monotherapy on days 1, 22, and 43 has been considered the preferred systemic treatment with concurrent radiation. It is an intensive regimen with considerable acute and chronic toxicities including mucositis, nausea, vomiting, myelosuppression, ototoxicity, nephrotoxicity, and neuropathy. A fair number of patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) are considered "not suitable" for this regimen. Even 30%‐40% of so called "fit" subjects from phase III randomized studies of high‐dose cisplatin could not complete the intended 3 cycles of chemotherapy with radiation.[3](#cam42139-bib-0003){ref-type="ref"}, [4](#cam42139-bib-0004){ref-type="ref"}, [5](#cam42139-bib-0005){ref-type="ref"} Traditionally, alternative platinum‐based regimens or cetuximab have been prescribed to patients who are unfit for high‐dose cisplatin. Wide variation and preference in utilization of these alternative regimens exist among oncologists in the United States as demonstrated by Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN) analysis.[6](#cam42139-bib-0006){ref-type="ref"} The 2 most common substituted regimens are weekly cetuximab and low‐dose cisplatin (30‐40 mg/m^2^). Cetuximab has been found to be inferior to high‐dose cisplatin [7](#cam42139-bib-0007){ref-type="ref"}, [8](#cam42139-bib-0008){ref-type="ref"} whereas weekly cisplatin is compared to high‐dose in only small prospective studies or retrospectively.[9](#cam42139-bib-0009){ref-type="ref"}, [10](#cam42139-bib-0010){ref-type="ref"}, [11](#cam42139-bib-0011){ref-type="ref"}, [12](#cam42139-bib-0012){ref-type="ref"}, [13](#cam42139-bib-0013){ref-type="ref"}, [14](#cam42139-bib-0014){ref-type="ref"}, [15](#cam42139-bib-0015){ref-type="ref"}, [16](#cam42139-bib-0016){ref-type="ref"}, [17](#cam42139-bib-0017){ref-type="ref"}, [18](#cam42139-bib-0018){ref-type="ref"}, [19](#cam42139-bib-0019){ref-type="ref"}, [20](#cam42139-bib-0020){ref-type="ref"}, [21](#cam42139-bib-0021){ref-type="ref"}, [22](#cam42139-bib-0022){ref-type="ref"}

Combination of weekly cisplatin and paclitaxel can be a potential substitute for high‐dose cisplatin and this regimen was developed by RTOG. Weekly cisplatin‐paclitaxel (CP) was effective in a randomized phase II study (RTOG 97‐03) with high rates of compliance.[23](#cam42139-bib-0023){ref-type="ref"} Despite the fact that combination chemotherapy might be better compared to single agent chemotherapy from neoadjuvant trials of HNSCC,[24](#cam42139-bib-0024){ref-type="ref"} the combination of CP is significantly underutilized.[6](#cam42139-bib-0006){ref-type="ref"} In this study, we retrospectively explored the efficacy and toxicity of weekly CP regimen and compared it with Cis when given concurrently with radiation for the treatment of HNSCC.

2. MATERIALS AND METHODS {#cam42139-sec-0006}
========================

Patients with LAHNSCC who received curative‐intent concurrent chemoradiation from 1 January 1998 to 31 December 2013 were identified from University of Iowa Oncology Registry, a prospectively maintained database of cancer patients. Intended chemotherapy regimen had to be either high‐dose cisplatin 100 mg/m^2^ (Cis) on day 1, 22, and 43 or the combination of cisplatin 20 mg/m^2^---paclitaxel 30 mg/m^2^ (CP) weekly x 7. Patients were excluded if: age \<18, nasopharyngeal or salivary gland as the primary site of tumor, 2 different synchronous primaries, presence of distant metastases, and receipt of induction chemotherapy. Study protocol was approved by the Institutional Review Board of University of Iowa. Per institution policy, individual patient consent was not required as this study was retrospective in nature and did not involve any intervention.

Demographic, disease‐, and treatment‐related data were captured through chart review by one of the authors. Comorbidities were scored using the Charlson Comorbidity Index (CCI). Smoking history was defined as "never" smoker if patient smoked \<100 cigarette/life time, "former" smoker if quit before development of symptoms from index tumor otherwise regarded as "current" smoker. All patients underwent a thorough staging work‐up which at a minimum included endoscopic examination of aero‐digestive tract, contrast‐enhanced neck CT, and CT of the chest or PET/CT prior to initiation of definitive therapy. Disease sites were categorized as oral, oropharyngeal, hypopharyngeal, larynx, and other primaries based on location of index primary tumor. Toxicities were graded per CTCAE v4.0. Toxicities occurring in the first 90 days from the date of initiation of treatment were considered as acute, and recurrent toxicities were documented only once with highest grade. Late toxicities were recorded at 6, 12, and 24 months from the start of treatment. These included chronic kidney disease, impaired hearing affecting routine activities of daily life, inability to eat solid food, aspiration pneumonia, and neuropathy.

A minimum follow‐up time of 16 months was available for all surviving patients. All patients underwent response assessment after completion of treatment by endoscopic examination and neck imaging either through CT or PET/CT. Complete response (CR) was defined as no evidence of tumor at the site of primary tumor and in the regional nodes. Regional node had to be normal by size criteria or have no increase in FDG uptake on PET/CT at 3 months from treatment completion. Patients undergoing salvage neck dissection for possible residual tumor within 5 months of treatment completion were not considered to have regional recurrence. Loco‐regional failure/recurrence was defined as histologic identification of tumor at site of index tumor at any time after completion of therapy or 5 months after therapy in the regional nodes or death due to index cancer. This definition was adopted from RTOG1016 protocol (NCT NCT01302834). Treatment failure was defined as persistent disease at the site of index tumor after therapy.

To investigate differences in the demographic, clinicopathologic, and outcome variables between intended chemotherapy groups, chi‐squared (Fisher\'s exact test were appropriate), and Wilcoxon rank sum tests were used. Survival probabilities were estimated and plotted using the Kaplan‐Meier method. For locoregional control, time was calculated from diagnosis to treatment failure, loco‐regional recurrence, or death due to cancer. For distant control, time was calculated from diagnosis to distant recurrence or death due to any cause. For progression free survival, time was calculated from diagnosis to treatment failure, locoregional or distant recurrence, or death due to any cause. For overall survival, time was calculated from diagnosis to death due to any cause. To adjust for potential treatment selection bias, inverse probability score weighted Cox regression models were fit to evaluate differences in outcomes by intended treatment group. Propensity scores were derived from a logistic regression model adjusting for age, smoking status and exposure, ECOG performance status, Charlson Comorbidity Index, baseline laboratory values, primary site, and TN stage. Estimated effects are reported as hazard ratios (HR) along with 95% confidence intervals. All statistical testing was 2‐sided and assessed for significance at the 5% level using SAS v9.4 (SAS Institute, Cary, NC).

3. RESULTS {#cam42139-sec-0007}
==========

Out of 516 patients treated during the study period, 225 cases met the eligibility criteria of the study. Reasons for exclusion were adjuvant chemoradiation for high risk LAHNSCC (n = 180), receipt of induction chemotherapy (n = 45), use of alternative systemic therapy (n = 50), and others (n = 16). Cis group included 114 patients while CP group composed of 111 patients. Three patients had stage II disease (2 in Cis group and 1 CP group), while remaining patients had stage III or higher disease.

Baseline demographic and clinical data for all patients are summarized in Table [1](#cam42139-tbl-0001){ref-type="table"}. Patients prescribed Cis were younger (*P* \< 0.01) and more likely to be an active cigarette smoker (*P* \< 0.01); however, overall extent of exposure to tobacco was less compared to patients receiving CP (*P* \< 0.01). Distribution of patients was balanced with regard to performance status but subjects with higher morbidity (CCI) were more likely to receive CP (*P* = 0.01). Oropharynx was the most common site for the index tumor (75%) in both groups (*P* = 0.35). The mean dose of cisplatin received in Cis and CP groups was 239.0 mg/m^2^ (79.7% of intended) and 120.2 mg/m^2^ (85.8% of intended), respectively. Fifty‐nine (51.8%) patients in the Cis group and 68 (61.3%) in the CP group could not receive all the intended cycles or weeks of chemotherapy (*P* = 0.15). Switch to a different regimen was required in 13.2% versus 2.7% in patients receiving Cis versus CP, respectively. All patients received intensity modulated radiation therapy and completed the intended course of radiation (66‐70Gy) except for 3 patients in Cis and 2 in CP group. Table [2](#cam42139-tbl-0002){ref-type="table"} summarized intended versus delivered therapy.

###### 

Patient characteristics

  ---------------------------------------------------------------------------------------------------------------
  Variables                                        Cisplatin (Cis)\   Cisplatin + Paclitaxel (CP)\   *P*‐Value
                                                   n = 114 (%)        n = 111 (%)                    
  ------------------------------------------------ ------------------ ------------------------------ ------------
  Age (median)                                     53.0               57.0                           **\<0.01**

  Sex                                                                                                

  Male                                             84 (73.7)          84 (75.7)                      0.73

  Female                                           30 (26.3)          27 (24.3)                       

  Smoking                                                                                            

  Current                                          63 (55.3)          38 (34.2)                      **\<0.01**

  Former                                           30 (26.3)          51 (45.9)                       

  Never                                            21 (18.4)          22 (19.8)                       

  Extent of smoking (only smokers were included)                                                     

  ≥20 pack‐year                                    74 (79.6)          87 (97.8)                      **\<0.01**

  \<20 pack‐year                                   19 (20.4)          2 (2.3)                         

  ECOG performance status                                                                            

  ≤1                                               108 (94.7)         110 (99.1)                     0.12

  ≥2                                               6 (5.3)            1 (0.9)                         

  Charlson comorbidity index (mean)                0.3                0.5                            **0.01**

  Primary site of SCC                                                                                

  Oral                                             2 (1.8)            4 (3.6)                        0.35

  Oropharynx                                       85 (74.6)          84 (75.7)                       

  Hypopharynx                                      3 (2.6)            5 (4.5)                         

  Larynx                                           24 (21.1)          16 (14.4)                       

  Others                                           0 (0.0)            2 (1.8)                         

  Primary site T staging                                                                             

  T2                                               64 (56.1)          53 (47.7)                      0.33

  T3                                               28 (24.6)          28 (25.2)                       

  T4                                               22 (19.3)          30 (27.0)                       

  TNM staging                                                                                        

  II‐III                                           21 (18.4)          19 (17.1)                      0.80

  IVa‐Ivb                                          93 (81.6)          92 (82.9)                       
  ---------------------------------------------------------------------------------------------------------------
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###### 

Intended vs received therapy

  ------------------------------------------------------------------------------------------------------------
  Variables                                     Cisplatin (Cis)\   Cisplatin + Paclitaxel (CP)\   *P*‐value
                                                n = 114 (%)        n = 111 (%)                    
  --------------------------------------------- ------------------ ------------------------------ ------------
  Completion of prescribed chemotherapy                                                           

  No                                            59 (51.8)          68 (61.3)                      0.15

  Yes                                           55 (48.2)          43 (38.7)                       

  Mean cisplatin‐dose received                  239.0 mg/m2        120.2 mg/m2                    **\<0.01**

  Mean % of intended cisplatin dose delivered   79.7%              85.8%                          0.12

  Switch to a different systemic regimen                                                          

  No                                            99 (86.8)          108 (97.3)                     **\<0.01**

  Yes                                           15 (13.2)          3 (2.7)                         

  Carboplatin‐paclitaxel                        7                  3                               

  Cisplatin‐Paclitaxel                          8                  NA                              

  Receipt of intended radiation dose                                                              

  No                                            3 (2.6)            2 (1.8)                        1.00

  Yes                                           111 (97.4)         109 (98.2)                      

  Break in radiation therapy (≥5 days)                                                            

  No                                            113 (99.1)         107 (96.4)                     0.24

  Yes                                           1 (0.9)            3 (2.7)                         
  ------------------------------------------------------------------------------------------------------------

John Wiley & Sons, Ltd

All of the 225 patients were included in the efficacy analysis. CR was observed in 100 (87.7%) versus 98 (88.3%) patients in Cis versus CP groups, respectively. Complete response by primary site and nodes in Cis versus CP groups was 104 (91.2%) versus 100 (90%) and 99 (86.8%) versus 96 (86.5%), respectively. Salvage neck node dissection was performed in 1 patient in Cis group and 2 in CP group for residual disease. In Cis group persistent disease was noted in 9 subjects, (primary site only \[n = 3\], regional nodes only \[n = 3\], and at both sites \[n = 3\]). In CP group, 10 subjects had persistent disease (primary site only \[n = 2\] and at both sites \[n = 8\]). Response to therapy could not be determined in 5 subjects due to death prior to assessment (n = 4 in Cis group; n = 1 in CP group).

Median length of follow‐up was 58.5 months (2.1‐186.7 months) for the study. In the Cis group, 12 patients had a locoregional recurrence, 13 patients had a distant recurrence, and 41 patients died. Similarly in the CP group, 13 patients developed locoregional recurrence, 16 patients had a distant recurrence, 48 patients died. Unadjusted Kaplan‐Meier curves along with 2‐ and 5‐year estimates are presented in Figures [1](#cam42139-fig-0001){ref-type="fig"} and [2](#cam42139-fig-0002){ref-type="fig"} and Table [3](#cam42139-tbl-0003){ref-type="table"}. After adjusting potential treatment selection bias, no significant differences between the high‐dose cisplatin and CP regimens for overall survival (HR 0.85, 95% CI 0.59‐1.21, *P* = 0.36), progression free survival (HR 0.88, 95% CI 0.62‐1.24, *P* = 0.46), locoregional control (HR 0.77, 95% CI 0.52‐1.15, *P* = 0.21), and distant control (HR 0.87, 95% CI 0.61‐1.23, *P* = 0.42) were evident.

![Overall and progression free survival by intended chemotherapy](CAM4-8-2730-g001){#cam42139-fig-0001}

![Locoregional and distant control by intended chemotherapy](CAM4-8-2730-g002){#cam42139-fig-0002}

###### 

2‐ and 5‐year efficacy outcomes according to intended chemotherapy assignment

  Outcome                     Intended regimen   2 years (95% CI)   5 years (95% CI)
  --------------------------- ------------------ ------------------ ------------------
  Overall survival            Cisplatin          89% (82%‐94%)      74% (65%‐82%)
  Cisplatin‐Paclitaxel        83% (74%‐89%)      65% (55%‐73%)      
  Progression free survival   Cisplatin          77% (68%‐84%)      68% (58%‐76%)
  Cisplatin‐Paclitaxel        75% (66%‐82%)      61% (51%‐69%)      
  Locoregional control        Cisplatin          79% (70%‐85%)      74% (65%‐81%)
  Cisplatin‐Paclitaxel        76% (67%‐83%)      69% (60%‐77%)      
  Distant control             Cisplatin          83% (75%‐89%)      73% (63%‐80%)
  Cisplatin‐Paclitaxel        65% (55%‐73%)      65% (55%‐73%)      
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Toxicities of chemotherapy regimens were assessed according to Common Toxicity Criteria of Adverse Events (CTCAE) version 4.0. Due to the retrospective nature of the study, mucositis could not be assessed reliably from patient\'s electronic records. Among the acute toxicities, patients receiving high‐dose cisplatin had higher incidence of grade ≥ 3 nausea, acute kidney injury (AKI), and presence of ototoxicity, whereas more patients in combination chemotherapy group required feeding tube placement. Distribution of grade 3 or higher vomiting, neuropathy, febrile neutropenia, and any hospitalization was similar between the 2 groups. Assessment of chronic toxicities during 6‐24 months after treatment revealed statistically higher incidence of chronic kidney disease, ototoxicity, and aspiration pneumonia in patients who received high‐dose cisplatin whereas feeding tube dependency was more common in combination chemotherapy group (Table [4](#cam42139-tbl-0004){ref-type="table"}).

###### 

Acute and chronic toxicities of treatment

  -----------------------------------------------------------------------------------------
  Toxicities   Cisplatin (Cis)\          Cisplatin‐Paclitaxel\                 *P*‐Value
               n = 114 (%)               (CP) n = 111 (%)                      
  ------------ ------------------------- ----------------------- ------------- ------------
  Acute        Hospitalization                                                 

               No                        69 (60.5)               60 (54.1)     0.33

               Yes                       45 (39.5)               51 (45.9)      

               Febrile neutropenia                                             

               No                        104 (91.2)              104 (93.7)    0.48

               Yes                       10 (8.8)                7 (6.3)        

               Acute kidney injury                                             

               Grade ≤ 2                 107 (93.9)              111 (100.0)   **0.01**

               Grade ≥ 3                 7 (6.1)                 0 (0.0)        

               Nausea                                                          

               Grade ≤ 2                 85 (74.6)               95 (85.6)     **0.04**

               Grade ≥ 3                 29 (25.4)               16 (14.4)      

               Vomiting                                                        

               Grade ≤ 2                 93 (81.6)               96 (86.5)     0.32

               Grade ≥ 3                 21 (18.4)               15 (13.5)      

               Neuropathy                                                      

               Grade ≤ 2                 114 (100.0)             110 (100.0)    

               Ototoxicity (any)                                               

               No                        94 (82.5)               105 (94.5)    **\<0.01**

               Yes                       20 (17.5)               5 (4.6)        

               Neutropenia                                                     

               Grade ≤ 2                 102 (89.5)              106 (95.5)    0.09

               Grade ≥ 3                 12 (10.5)               5 (4.5)        

               Thrombocytopenia                                                

               Grade ≤ 2                 114 (100.0)             109 (98.2)    0.24

               Grade ≥ 3                 0 (0.0)                 2 (1.8)        

               Anemia                                                          

               Grade ≤ 2                 110 (96.5)              104 (93.7)    0.33

               Grade ≥ 3                 4 (3.5)                 7 (6.3)        

               Feeding tube required                                           

               No                        35 (30.7)               6 (5.4)       **\<0.01**

               Yes                       79 (69.3)               105 (94.6)     

  Chronic      Chronic kidney disease                                          

               No                        93 (84.3)               107 (98.2)    **\<0.01**

               Yes                       16 (14.7)               2 (1.8)        

               Ototoxicity                                                     

               No                        86 (80.4)               105 (96.3)    **\<0.01**

               Yes                       21 (19.6)               4 (3.7)        

               Neuropathy                                                      

               No                        102 (95.3)              108 (99.1)    0.12

               Yes                       5 (4.7)                 1 (0.9)        

               Aspiration pneumonia                                            

               No                        94 (87.9)               107 (99.1)    **\<0.01**

               Yes                       13 (12.1)               1 (0.9)        

               Feeding tube dependency                                         

               No                        61 (57.0)               34 (31.2)     **\<0.01**

               Yes                       46 (43.0)               77 (68.8)      
  -----------------------------------------------------------------------------------------

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42139-sec-0008}
=============

The goal of this study was to compare low‐dose‐cisplatin‐based combination chemotherapy with high‐dose cisplatin in definitive concurrent chemoradiation setting for patients with LAHNSCC. Our findings suggest higher compliance, comparable efficacy, and significantly less acute toxicity with low‐dose CP combination chemotherapy.

Three‐weekly single agent high‐dose cisplatin is considered as the standard of care systemic therapy for definitive concurrent chemoradiation setting. Despite the irrefutable benefits, higher incidence of severe acute toxicities (16%‐47%) and relatively low compliance rates (60%‐70%) raise significant concern regarding tolerability of this regimens in the minds of treating physicians and patients.[3](#cam42139-bib-0003){ref-type="ref"}, [4](#cam42139-bib-0004){ref-type="ref"}, [5](#cam42139-bib-0005){ref-type="ref"}, [25](#cam42139-bib-0025){ref-type="ref"} In addition, long‐term follow‐up of RTOG91‐11 discovered significantly higher non‐cancer‐related mortality in patients who received high‐dose cisplatin concomitantly with radiation.[26](#cam42139-bib-0026){ref-type="ref"} Consequently, there has been an effort to reduce the treatment‐related complications without compromising anticancer activity. Weekly low dose cisplatin (30‐40mg/m2) is considered an alternative option to high dose cisplatin as it offers similar dose intensity, reduces chemotherapy‐related acute adverse events, and facilitates dose adjustments according to changes in patient\'s condition with relatively similar survival benefit as suggested by a meta‐analysis.[25](#cam42139-bib-0025){ref-type="ref"} Nevertheless, other studies have questioned this finding. Only randomized study comparing low (30 m/m^2^) versus high dose (100 mg/m^2^) cisplatin prospectively found inferior locoregional disease control with low dose cisplatin. While other studies revealed inferior overall survival with low‐dose cisplatin compare to high‐dose cisplatin.[20](#cam42139-bib-0020){ref-type="ref"}, [27](#cam42139-bib-0027){ref-type="ref"}, [28](#cam42139-bib-0028){ref-type="ref"} Despite the controversy of high and low dose cisplatin, 15% of LAHNSCC patients in the United States receive weekly low‐dose cisplatin with radiation according to LORHAN analysis. Cetuximab, an epidermal growth factor receptor monoclonal antibody, is another alternative option to high or low‐dose cisplatin as it is considered to have better side‐effect profile.[29](#cam42139-bib-0029){ref-type="ref"} However, recent studies have confirmed that it is inferior to high‐dose cisplatin even in HPV positive oropharyngeal LAHNSCC which is a considered as good prognostic disease.[7](#cam42139-bib-0007){ref-type="ref"}, [8](#cam42139-bib-0008){ref-type="ref"}, [10](#cam42139-bib-0010){ref-type="ref"}, [12](#cam42139-bib-0012){ref-type="ref"}, [14](#cam42139-bib-0014){ref-type="ref"}

Other substitutes to high‐dose cisplatin include combinatorial chemotherapy regimens involving multiple radiosensitizing agents. Combinatorial regimens could disturb varying aspect of tumor biology along with providing systemic effects. Since, survival benefit associated with concurrent chemoradiation is mainly due to improvement in locoregional control; multiagent radiosensitizing regimens may actually do better than single agent cisplatin. This is supported by the reversal in pattern of failure from locoregional recurrences to distant disease as seen in some of the studies that utilized multiagent regimens.[30](#cam42139-bib-0030){ref-type="ref"}, [31](#cam42139-bib-0031){ref-type="ref"}, [32](#cam42139-bib-0032){ref-type="ref"}, [33](#cam42139-bib-0033){ref-type="ref"}, [34](#cam42139-bib-0034){ref-type="ref"} MACH‐NC meta‐analysis on the use of chemotherapy also concluded that polychemotherapy either with platin or 5‐FU was not inferior to mono‐platin.[2](#cam42139-bib-0002){ref-type="ref"}, [35](#cam42139-bib-0035){ref-type="ref"} However, data comparing combination of relatively newer chemotherapeutic agents with high‐dose cisplatin monotherapy is regrettably lacking. Many centers have attempted to look at weekly carboplatin‐paclitaxel combination in concomitant chemoradiation setting. Not surprisingly, compliance was better and overall outcomes were comparable to historical control.[36](#cam42139-bib-0036){ref-type="ref"}, [37](#cam42139-bib-0037){ref-type="ref"}, [38](#cam42139-bib-0038){ref-type="ref"}, [39](#cam42139-bib-0039){ref-type="ref"}, [40](#cam42139-bib-0040){ref-type="ref"}, [41](#cam42139-bib-0041){ref-type="ref"} But these studies did not directly compare the combination therapy with single agent high‐dose cisplatin (Table [5](#cam42139-tbl-0005){ref-type="table"}).

###### 

Outcomes of studies utilizing platinum‐taxol regimens

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Primary sites of disease   Retrospective vs prospective                           Chemotherapy regimen     Number Of Patients   Overall Survival (OS)                          Progression Free Survival (PFS)                Complete response rate (CR)                   Ref
  -------------------------- ------------------------------------------------------ ------------------------ -------------------- ---------------------------------------------- ---------------------------------------------- --------------------------------------------- ---------------
  All HNSCC                  Prospective\                                           Carboplatin 100\         55                   3y‐45%\                                        3y‐36%\                                        52%                                           35
                             Single arm                                             Paclitaxel 40                                 5y‐35%                                         5y‐36%                                                                                       

  All HNSCC                  Prospective\                                           Carboplatin AUC1\        43                   NA[^†^](#cam42139-note-0002){ref-type="fn"}\   NA[^†^](#cam42139-note-0002){ref-type="fn"}\   65%                                           36
                             Single arm                                             Paclitaxel 60mg/m2                            5y‐40%                                         5y‐70%                                                                                       

  All HNSCC                  Prospective (UMC0221)                                  Carboplatin AUC1\        35                   3y‐88%\                                        NA[^†^](#cam42139-note-0002){ref-type="fn"}\   NA[^†^](#cam42139-note-0002){ref-type="fn"}   37
                                                                                    Paclitaxel 30 mg/m2                           NA[^†^](#cam42139-note-0002){ref-type="fn"}    NA[^†^](#cam42139-note-0002){ref-type="fn"}                                                  

  All HNSCC                  Retrospective\                                         Cisplatin 20mg/m2\       111                  2y‐83%\                                        2y‐77%\                                        88%                                           Current study
                             (two groups --High dose Cis group data nor shown)      Paclitaxel 30 mg/m2                           5y‐65%                                         5y‐61%                                                                                       

  Oropharyngeal (OP) only    Retrospective\                                         Carboplatin AUC2\        160                  3y‐81%\                                        NA[^†^](#cam42139-note-0002){ref-type="fn"}\   NA[^†^](#cam42139-note-0002){ref-type="fn"}   39
                             (one group)                                            Paclitaxel 40                                 5y‐70%                                         5y‐64%                                                                                       

  All HNSCC                  Retrospective\                                         Carboplatin 100 mg/m2\   60                   3y‐48%                                         3y‐48%                                         75%                                           34
                             (one group)                                            Paclitaxel 45 mg/m2                                                                                                                                                                       

  HPV + OP                   Retrospective\                                         Carboplatin\             59                   3y‐88%\                                        3y‐84%\                                        NA[^†^](#cam42139-note-0002){ref-type="fn"}   38
                             (3 groups, weekly Cis, and Cetuximab data not shown)   Paclitaxel                                    5y‐78%                                         5y‐80%                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: Not available or applicable due to difference in methodology.
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Our study aimed to compare a multiagent combination of 2 strong radiosensitizing chemotherapies, cisplatin and paclitaxel, against high‐dose cisplatin to minimize toxicity and improve compliance without jeopardizing tumor control. Outcomes of patients who received CP combination chemotherapy with definitive radiation seems to be numerically inferior at 5‐year time‐point but these differences were not significant. One of the common concerns over low‐dose chemotherapy is their limited efficacy toward eradicating micrometastases affecting distant failure. However, distant control in our study was similar in both the groups. All acute and chronic toxicities that were different between the 2 groups were seen less frequently with combination chemotherapy except for requirement and dependency on feeding tube. Due to retrospective nature of the study, it is unclear why patients in combination chemotherapy group required feeding tube to be placed more often but this may be to prevent malnutrition as patients in this group were old, had higher co‐morbidity and larger primary (T4) tumor compare to high‐dose cisplatin group. Another explanation is patients in combination chemotherapy group had higher degree of swallowing dysfunction. This could suggest higher radiosensitizing potential of the CP regimen. Nonetheless, dependency on feeding tube was different only till 6 months, after that both groups were similar with regards to requiring feeding tube to maintain adequate nutrition.

Our study has several limitations. Due to retrospective nature of the study there is inherent selection bias toward intended chemotherapy assignment for patients. Data pertaining to HPV or p‐16 positivity was lacking for most patients. Since, frequency of oropharyngeal squamous cell carcinoma is similar in both group therefore we believe this should not have affected the results. Toxicity data in our study were captured from patients' electronic health records and due to differences in documentation among treating physicians, there could be more differences which could not be captured.

5. CONCLUSIONS {#cam42139-sec-0009}
==============

In patients with LAHNSCC who are not fit for high‐ or low‐dose cisplatin, weekly CP regimen can serve as an alternative systemic therapy with radiation. Our data suggest that it is well tolerated, easy to deliver and have similar efficacy. Our findings need further evaluation through prospective studies.
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